Medicare Part B Drug Payments: Impact of Price Substitutions Based on 2022 Average Sales Prices
When Congress established average sales price (ASP) as the basis for Medicare Part B drug reimbursement, it also provided a mechanism for monitoring market prices and limiting potentially excessive Medicare payment amounts. Section 1847A(d)(1)-(3) of the Social Security Act mandates that the Office of Inspector General (OIG) compare ASPs with average manufacturer prices (AMPs) and the widely available market price, if any. If OIG finds that the ASP for a drug exceeded the AMP by 5 percent in the two previous quarters or three of the previous four quarters, the Secretary of Health and Human Services may substitute the reimbursement amount with a lower calculated rate. Over the past decade, OIG has produced annual reports aggregating the results of our mandated quarterly ASP-to-AMP comparisons. This annual report will quantify the savings to Medicare and its beneficiaries that are a direct result of CMS's price substitution policy based on 2022 ASPs, and may offer recommendations for Medicare to achieve additional savings.
|Announced or Revised||Agency||Title||Component||Report Number(s)||Expected Issue Date (FY)|
|November 2023||Centers for Medicare and Medicaid Services||Medicare Part B Drug Payments: Impact of Price Substitutions Based on 2022 Average Sales Prices||Office of Evaluation and Inspections||OEI-03-24-00080||2024|